SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Drugs that provide the splice of life: Motor neurons relay signals from the nervous system to muscle fibers. In patients with spinal muscular atrophy, a protein required for the survival of these neurons is deficient or missing altogether, so the neurons gradually die and the patients' muscles waste away. The disease is currently untreatable. Naryshkin et al. discovered small-molecule drugs that cause cells to produce the missing protein by altering how a specific mRNA is put together, or “spliced” (see the Perspective by Vigevani and Valcárcel). When the researchers used the drugs to treat diseased mice, the mice showed marked improvement in muscle mass, motor function, and survival. Science , this issue p. 688 ; see also p. 624
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These screens, which are typically conducted in genetically engineered cell lines that harbour the target of interest, led to the discovery of the splice modulators risdiplam106 and branaplam107 for the treatment of spinal muscular atrophy”
From Human disease models in drug development (2023) · cites this paper as [106]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
GMAP: A genomic mapping and alignment program for mRNA and EST sequences
Wu, T. D., & Watanabe, C. K. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti310 · Cited by 2,354
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Cited by
Items 101–200 of 533
Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease
Marabti, E. E., & Abdel-Wahab, O. I. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.04.005 · Cited by 73
McGovern, V. L., Iyer, C. C., Arnold, W. D., Gombash, S. E., Zaworski, P. G., Blatnik, A. J., Foust, K. D., & Burghes, A. H. M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv283 · Cited by 69
Small molecule–RNA targeting: starting with the fundamentals
Hargrove, A. E. (2020) · Chemical Communications · doi:10.1039/d0cc06796b · Cited by 70
New approaches to target RNA binding proteins
Julio, A. R., & Backus, K. M. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.12.006 · Cited by 76
Current Treatment Options in Neurology—SMA Therapeutics
Waldrop, M. A., & Kolb, S. J. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0568-z · Cited by 72
Mutually exclusive alternative splicing of pre‐mRNAs
Jin, Y., Dong, H., Shi, Y., & Bian, L. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1468 · Cited by 80
“For example, sequence-specific antisense oligonucleotides (ASOs) can restore the inclusion of exon 7 by blocking its splicing repressor element in the SMN2 transcript, providing a most elegant strategy for the gene therapy of spinal muscular atrophy (Hua et al., 2011; Naryshkin et al., 2014).”
BackgroundAslesh, T., & Yokota, T. (2022) · Cells · doi:10.3390/cells11030417 · Cited by 72
Bogdanik, L. P., Osborne, M. A., Davis, C., Martin, W. P., Austin, A., Rigo, F., Bennett, C. F., & Lutz, C. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509758112 · Cited by 63
Woll, M. G., Qi, H., Turpoff, A., Zhang, N., Zhang, X., Chen, G., Li, C., Huang, S., Yang, T., Moon, Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00460 · Cited by 69
Self-citationZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy
Kannan, A., Jiang, X., He, L., Ahmad, S., & Gangwani, L. (2019) · Brain · doi:10.1093/brain/awz373 · Cited by 71
“…(3-fold) of Z-SMA mice compared to other reported splicing modifiers and gene therapy methods used in SMA 7 mice raise the possibility of contribution of unanticipated toxic and off target effects of ZPR1 overexpression (Singh et al., 2009, 2017; Naryshkin et al., 2014; Meyer et al., 2015).”
BackgroundFeng, Z., Ling, K., Zhao, X., Zhou, C., Karp, G. M., Welch, E. M., Naryshkin, N. A., Ratni, H., Chen, K. S., Metzger, F., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv629 · Cited by 70
Self-citationTseng, Y., Chen, C., Jong, Y., Chang, F., & Lo, Y. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.023 · Cited by 66
Drug treatment for spinal muscular atrophy types II and III
Wadman, R. I., van der Pol, W. L., Bosboom, W. M., Asselman, F., van den Berg, L. H., Iannaccone, S. T., & Vrancken, A. F. J. E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006282.pub5 · Cited by 79
Disney, M. D., Dwyer, B. G., & Childs‐Disney, J. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034769 · Cited by 68
RNA processing in skeletal muscle biology and disease
Hinkle, E. R., Wiedner, H. J., Black, A. J., & Giudice, J. (2019) · Transcription · doi:10.1080/21541264.2018.1558677 · Cited by 63
“[172] Naryshkin NA, Weetall M, Dakka A, et al.”
BackgroundNuisance compounds in cellular assays
Dahlin, J. L., Auld, D. S., Rothenaigner, I., Haney, S., Sexton, J. Z., Nissink, J. W. M., Walsh, J. J., Lee, J. A., Strelow, J. M., Willard, F. S., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.021 · Cited by 66
“For instance, in the identification of SMN2 splicing modifiers, primary luciferase gene reporter hits were confirmed with quantitative PCR for the full-length SMN2mg and Δ7 transcripts (Naryshkin et al., 2014).”
BackgroundThe Molecular Basis of FIX Deficiency in Hemophilia B
Shen, G., Gao, M., Cao, Q., & Li, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052762 · Cited by 70
Sintusek, P., Catapano, F., Angkathunkayul, N., Marrosu, E., Parson, S. H., Morgan, J. E., Muntoni, F., & Zhou, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155032 · Cited by 66
Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy
Shorrock, H. K., Gillingwater, T. H., & Groen, E. J. N. (2018) · Drugs · doi:10.1007/s40265-018-0868-8 · Cited by 67
“These studies demonstrated an improvement in motor function, protection of the neuromuscular system from degeneration and increased survival in SMA model mice [42].”
BackgroundHit Triage and Validation in Phenotypic Screening: Considerations and Strategies
Vincent, F., Loria, P. M., Weston, A. D., Steppan, C. M., Doyonnas, R., Wang, Y., Rockwell, K. L., & Peakman, M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.08.009 · Cited by 64
Arnold, E. S., & Fischbeck, K. H. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64076-5.00038-7 · Cited by 73
Small Molecule-Based Pattern Recognition To Classify RNA Structure
Eubanks, C. S., Forte, J. E., Kapral, G. J., & Hargrove, A. E. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11087 · Cited by 59
Therapeutic approaches for spinal muscular atrophy (SMA)
Scoto, M., Finkel, R. S., Mercuri, E. M., & Muntoni, F. (2017) · Gene Therapy · doi:10.1038/gt.2017.45 · Cited by 66
Mechanistic Principles of Antisense Targets for the Treatment of Spinal Muscular Atrophy
Singh, N. N., Lee, B. M., DiDonato, C. J., & Singh, R. N. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.101 · Cited by 66
Improvement of SMN2 Pre-mRNA Processing Mediated by Exon-Specific U1 Small Nuclear RNA
Mas, A. D., Rogalska, M. E., Bussani, E., & Pagani, F. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.12.009 · Cited by 61
SMN deficiency disrupts gastrointestinal and enteric nervous system function in mice
Gombash, S. E., Cowley, C. J., Fitzgerald, J. A., Iyer, C. C., Fried, D. E., McGovern, V. L., Williams, K. C., Burghes, A. H. M., Christofi, F. L., Gulbransen, B. D., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv127 · Cited by 65
Molecular basis of differential 3′ splice site sensitivity to anti-tumor drugs targeting U2 snRNP
Vigevani, L., Gohr, A., Webb, T. R., Irimia, M., & Valcárcel, J. (2017) · Nature Communications · doi:10.1038/s41467-017-02007-z · Cited by 65
Small molecule targeting of biologically relevant RNA tertiary and quaternary structures
Zafferani, M., & Hargrove, A. E. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.003 · Cited by 60
“Treatment of mice models of various SMA types increased body weight, life expectancy, and motility, making small molecule 15 a promising clinical candidate (Naryshkin et al., 2014).”
BackgroundArmbruster, N., Lattanzi, A., Jeavons, M., Van Wittenberghe, L., Gjata, B., Marais, T., Martin, S., Vignaud, A., Voit, T., Mavilio, F., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.60 · Cited by 54
The piperazine scaffold for novel drug discovery efforts: the evidence to date
Romanelli, M. N., Manetti, D., Braconi, L., Dei, S., Gabellini, A., & Teodori, E. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2103535 · Cited by 53
Zhou, H., Meng, J., Marrosu, E., Janghra, N., Morgan, J. E., & Muntoni, F. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv329 · Cited by 52
Geerts, H., Wikswo, J. P., van der Graaf, P. H., Bai, J. P. F., Gaiteri, C., Bennett, D. A., Swalley, S. E., Schuck, E. L., Kaddurah‐Daouk, R., Tsaioun, K., et al. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12478 · Cited by 56
Spinal Muscular Atrophy Therapeutics: Where do we Stand?
d’Ydewalle, C. V. O., & Sumner, C. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0337-y · Cited by 57
“These modifiers also increased motor function and dramatically extended survival of 2 different SMA mouse models when administered systemically by oral gavage and/or by intraperitoneal administration [106].”
BackgroundInfluentialSingle-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease
Rodríguez‐Muela, N., Litterman, N. K., Norabuena, E. M., Mull, J. L., Galazo, M. J., Sun, C., Ng, S., Makhortova, N. R., White, A. J., Lynes, M. M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.035 · Cited by 55
Self-citationHilimire, T. A., Chamberlain, J. M., Anokhina, V. S., Bennett, R. P., Swart, O., Myers, J. R., Ashton, J. M., Stewart, R. A., Featherston, A. L., Gates, K., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00052 · Cited by 54
A cross-linking approach to map small molecule-RNA binding sites in cells
Velagapudi, S. P., Li, Y., & Disney, M. D. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.001 · Cited by 52
Tessaro, F., & Scapozza, L. (2020) · Molecules · doi:10.3390/molecules25122749 · Cited by 57
Nonviral delivery systems for antisense oligonucleotide therapeutics
Huang, S. Q., Hao, X., Li, Y., Wu, J., Xiang, D., & Luo, S. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00292-4 · Cited by 59
Longitudinal characterization of biomarkers for spinal muscular atrophy
Bonati, U., Holiga, Š., Hellbach, N., Risterucci, C., Bergauer, T., Tang, W., Hafner, P., Thoeni, A., Bieri, O., Gerlach, I., et al. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.406 · Cited by 50
Self-citationMoving towards treatments for spinal muscular atrophy: hopes and limits
Wirth, B., Barkats, M., Martinat, C., Sendtner, M., & Gillingwater, T. H. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1041375 · Cited by 49
Ottesen, E. W., Singh, N. N., Luo, D., Kaas, B., Gillette, B., Seo, J., Jorgensen, H. J., & Singh, R. N. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad259 · Cited by 54
Specificity, synergy, and mechanisms of splice-modifying drugs
Ishigami, Y., Wong, M. S., Martí‐Gómez, C., Ayaz, A., Kooshkbaghi, M., Hanson, S. M., McCandlish, D. M., Krainer, A. R., & Kinney, J. B. (2024) · Nature Communications · doi:10.1038/s41467-024-46090-5 · Cited by 50
History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
Qiu, J., Wu, L., Qu, R., Jiang, T., Bai, J., Sheng, L., Feng, P., & Sun, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.942976 · Cited by 51
“It enhances the spliceosome recognition of exon 7 by stabilizing the ribonucleoprotein complex (RNP; Naryshkin et al., 2014; Palacino et al., 2015; Sivaramakrishnan et al., 2017).”
BackgroundSteering research on mRNA splicing in cancer towards clinical translation
Anczuków, O., Allain, F. H. ‐., Angarola, B. L., Black, D. L., Brooks, A. N., Cheng, C., Conesa, A., Crosse, E. I., Eyras, E., Guccione, E., et al. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00750-2 · Cited by 59
Modulation of Alternative Splicing with Chemical Compounds in New Therapeutics for Human Diseases
Ohe, K., & Hagiwara, M. (2015) · ACS Chemical Biology · doi:10.1021/cb500697f · Cited by 52
Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research
Brown, D. G., & Wobst, H. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00797 · Cited by 48
Contemporary Progress and Opportunities in RNA-Targeted Drug Discovery
Garner, A. L. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00020 · Cited by 55
Pre-mRNA splicing-associated diseases and therapies
Love, S. L., Emerson, J. D., Koide, K., & Hoskins, A. A. (2023) · RNA Biology · doi:10.1080/15476286.2023.2239601 · Cited by 54
Discovery of small molecules that target a tertiary-structured RNA
Menichelli, E., Lam, B. J., Wang, Y., Wang, V. S., Shaffer, J., Tjhung, K. F., Bursulaya, B. D., Nguyen, T. N., Vo, T., Alper, P. B., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213117119 · Cited by 49
“Two independent studies used a high-throughput, cell-based screen to identify compounds that promote the inclusion of a skipped exon in SMN2 pre-mRNA, thus restoring the expression of the SMN protein that is lacking in patients with spinal muscular atrophy (9, 10).”
The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy
Arnold, W. D., McGovern, V. L., Sanchez, B., Li, J., Corlett, K. M., Kolb, S. J., Rutkove, S. B., & Burghes, A. H. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.12.014 · Cited by 50
Photoaffinity labelling with small molecules
Homan, R. A., Lapek, J. D., Woo, C. M., Niessen, S., Jones, L. H., & Parker, C. G. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00308-4 · Cited by 65
Czech, C., Tang, W., Bugawan, T. L., Mano, C., Horn, C., Iglesias, V. A., Fröhner, S., Zaworski, P. G., Paushkin, S. V., Chen, K. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139950 · Cited by 45
Self-citationValeur, E., & Jimonet, P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00378 · Cited by 43
The power of combining phenotypic and target-focused drug discovery
Heilker, R., Lessel, U. F., & Bischoff, D. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.10.009 · Cited by 49
A deep learning approach to identify gene targets of a therapeutic for human splicing disorders
Gao, D., Morini, E., Salani, M., Krauson, A. J., Chekuri, A., Sharma, N., Ragavendran, A., Erdin, S., Logan, E. M., Li, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23663-2 · Cited by 54
Self-citationIyer, C. C., McGovern, V. L., Murray, J. D., Gombash, S. E., Zaworski, P. G., Foust, K. D., Janssen, P. M. L., & Burghes, A. H. M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv332 · Cited by 50
Zaworski, P. G., von Herrmann, K. M., Taylor, S. J., Sunshine, S., McCarthy, K., Risher, N., Newcomb, T. M., Weetall, M. L., Prior, T. W., Swoboda, K. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150640 · Cited by 47
“Existing methods to measure SMN protein levels include an Elecsys platform-based assay developed by Roche Diagnostics to measure SMN in whole blood [19], an electrochemiluminescence immunoassay (ECLIA) to measure SMN in buccal cells [20], an SMN-ELISA developed to measure SMN in peripheral blood mononuclear cells [21]…”
MethodSelf-citationLOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies
Rizzacasa, B., Morini, E., Pucci, S., Murdocca, M., Novelli, G., & Amati, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020290 · Cited by 49
Pawellek, A., Ryder, U., Tammsalu, T., King, L. J., Kreinin, H., Ly, T., Hay, R. T., Hartley, R. C., & Lamond, A. I. (2017) · eLife · doi:10.7554/elife.27402 · Cited by 46
Kletzl, H., Marquet, A., Günther, A., Tang, W., Heuberger, J. A. A. C., Groeneveld, G. J., Birkhoff, W. A. J., Mercuri, E. M., Lochmüller, H., Wood, C. L., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.10.001 · Cited by 48
Self-citationSplicing mutations in inherited retinal diseases
Weisschuh, N., Buena‐Atienza, E., & Wissinger, B. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100874 · Cited by 46
Pluripotent Stem Cell Platforms for Drug Discovery
Chen, K. G., Mallon, B. S., Park, K., Robey, P. G., McKay, R. D. G., Gottesman, M. M., & Zheng, W. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.009 · Cited by 43
Self-citationELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia
Morini, E., Gao, D., Montgomery, C. M., Salani, M., Mazzasette, C., Krussig, T. A., Swain, B., Dietrich, P., Narasimhan, J., Gabbeta, V., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.009 · Cited by 45
“We specifically chose fibroblast lines because they are the primary choice for assessing the splicing selectivity of small molecules.(78,79) Our evaluation of the geneexpression analysis conservatively restricted interpretation to genes that met an FDR <0.”
Self-citationTarget-Directed Approaches for Screening Small Molecules against RNA Targets
Haniff, H. S., Knerr, L., Chen, J. L., Disney, M. D., & Lightfoot, H. L. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220922802 · Cited by 44
Markati, T., Fisher, G., Ramdas, S., & Servais, L. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2056836 · Cited by 43
“Brain penetration and increases in SMN protein level have also been demonstrated with other oral SMN2 splicing modifiers with chemical similarities to risdiplam [16].”
BackgroundRescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA
Donadon, I., Bussani, E., Riccardi, F., Licastro, D., Romano, G., Pianigiani, G., Pinotti, M., Konstantinova, P. S., Evers, M. M., Lin, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz469 · Cited by 44
Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia
Ajiro, M., Awaya, T., Kim, Y. J., Iida, K., Denawa, M., Tanaka, N., Kurosawa, R., Matsushima, S., Shibata, S., Sakamoto, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24705-5 · Cited by 43
RNA-Targeted Therapies and High-Throughput Screening Methods
Zhu, S., Rooney, S., & Michlewski, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082996 · Cited by 41
Genetic therapies for inherited neuromuscular disorders
Scoto, M., Finkel, R. S., Mercuri, E. M., & Muntoni, F. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30140-8 · Cited by 45
Ando, S., Suzuki, S., Okubo, S., Ohuchi, K., Takahashi, K., Nakamura, S., Shimazawa, M., Fuji, K., & Hara, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-74346-9 · Cited by 44
Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39
Campagne, S., Jutzi, D., Malard, F., Matoga, M., Romane, K., Feldmüller, M., Colombo, M., Ruepp, M., & Allain, F. H. ‐. (2023) · Nature Communications · doi:10.1038/s41467-023-40254-5 · Cited by 45
Tajnik, M., Rogalska, M. E., Bussani, E., Barbon, E., Balestra, D., Pinotti, M., & Pagani, F. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006082 · Cited by 42
Blocking p62-dependent SMN degradation ameliorates spinal muscular atrophy disease phenotypes
Rodríguez‐Muela, N., Parkhitko, A. A., Graß, T., Gibbs, R. M., Norabuena, E. M., Perrimon, N., Singh, R., & Rubin, L. L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95231 · Cited by 43
Self-citationTreating neonatal spinal muscular atrophy: A 21st century success story?
Tizzano, E. F. (2019) · Early Human Development · doi:10.1016/j.earlhumdev.2019.104851 · Cited by 45
Maretina, M. A., Zheleznyakova, G. Y., Lanko, K., Egorova, A., Баранов, В. С., & Kiselev, A. (2018) · Current Genomics · doi:10.2174/1389202919666180101154916 · Cited by 48
“Indeed, chemical classes of small molecules modulating SMN2 exon 7 inclusion were shown to ameliorate phenotype and prolong survival of SMA model mice as a result of restoration of SMN2 splicing and SMN protein level [60].”
BackgroundMenduti, G., Rasà, D. M., Stanga, S., & Boido, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.592234 · Cited by 41
Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling
Beghini, D. G., Kasai-Brunswick, T. H., & Henriques‐Pons, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042392 · Cited by 42
“Administration of this compound to mice led to increased survival of motor neurons, higher SMN protein levels, motor function improvement, and neuromuscular circuit protection [92].”
BackgroundMore than a messenger: Alternative splicing as a therapeutic target
Black, A. J., Gamarra, J. R., & Giudice, J. (2019) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2019.06.006 · Cited by 42
Gene-Targeting Therapeutics for Neurological Disease: Lessons Learned from Spinal Muscular Atrophy
Ravi, B., Chan-Cortés, M. H., & Sumner, C. J. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-070119-115459 · Cited by 39
RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays
Tang, Z., Zhao, J., Pearson, Z., Bošković, Ž., & Wang, J. (2021) · Molecules · doi:10.3390/molecules26082263 · Cited by 39
Mavrou, A., & Oltean, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.013 · Cited by 43
Applying Deep Neural Network Analysis to High-Content Image-Based Assays
Yang, S. J., Lipnick, S. L., Makhortova, N. R., Venugopalan, S., Fan, M., Armstrong, Z., Schlaeger, T. M., Deng, L., Chung, W. K., O’Callaghan, L., et al. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219857715 · Cited by 36
Self-citationZhao, X., Feng, Z., Ling, K., Mollin, A., Sheedy, J., Yeh, S., Petruska, J. M., Narasimhan, J., Dakka, A., Welch, E. M., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw062 · Cited by 39
Self-citationAlternative Splicing in Genetic Diseases: Improved Diagnosis and Novel Treatment Options
Bergsma, A. J., van der Wal, E., Broeders, M., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.008 · Cited by 50
Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly
Jagtap, P. K. A., Kubelka, T., Soni, K., Will, C. L., Garg, D., Sippel, C., Kapp, T. G., Potukuchi, H. K., Schorpp, K., Hadian, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19514-1 · Cited by 39
Iijima, T., Hidaka, C., & Iijima, Y. (2016) · Neuroscience Research · doi:10.1016/j.neures.2016.01.010 · Cited by 36
Pinard, E., Green, L. G., Reutlinger, M., Weetall, M. L., Naryshkin, N. A., Baird, J. D., Chen, K. S., Paushkin, S. V., Metzger, F., & Ratni, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00406 · Cited by 34
Self-citationLorenz, D. A., Roest, S. V., Larsen, M. J., & Garner, A. L. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217717944 · Cited by 38
Nguyen, L. D., Chau, R. K., & Krichevsky, A. M. (2021) · Genes · doi:10.3390/genes12122005 · Cited by 37
Jablonka, S., & Sendtner, M. (2017) · Gene Therapy · doi:10.1038/gt.2017.46 · Cited by 40
Ohuchi, K., Funato, M., Kato, Z., Seki, J., Kawase, C., Tamai, Y., Ono, Y., Nagahara, Y., Noda, Y., Kameyama, T., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0059 · Cited by 34
Integrated generation of induced pluripotent stem cells in a low-cost device
Lin, H., Li, Q., Du, Q., Wang, O., Wang, Z., Akert, L., Carlson, M. A., Zhang, C., Subramanian, A., Zhang, C., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.027 · Cited by 36
Torres‐Benito, L., Schneider, S. M., Rombo, R., Ling, K., Grysko, V., Upadhyay, A., Kononenko, N. L., Rigo, F., Bennett, C. F., & Wirth, B. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.05.008 · Cited by 44
“While SMN-ASOs, small molecules, or SMN gene therapy show promising results in pre- or early-treated symptomatic SMA individuals, treatment in more advanced stages of the disease show onlymoderate or even no effect.(1,31,33,38,39) For these SMA-affected individuals, amelioration or even stopping the disease progressio…”
BackgroundSelf-citationHallmarks of Splicing Defects in Cancer: Clinical Applications in the Era of Personalized Medicine
Rahman, M. A., Nasrin, F., Bhattacharjee, S., & Nandi, S. (2020) · Cancers · doi:10.3390/cancers12061381 · Cited by 33
Ojala, K. S., Reedich, E. J., DiDonato, C. J., & Meriney, S. D. (2021) · Brain Sciences · doi:10.3390/brainsci11020194 · Cited by 39
Spinal muscular atrophy: from tissue specificity to therapeutic strategies
Iascone, D. M., Henderson, C. E., & Lee, J. (2015) · F1000Prime Reports · doi:10.12703/p7-04 · Cited by 35
Human induced pluripotent stem cells: A disruptive innovation
Vos, J. D., Bouckenheimer, J., Sansac, C., Lemaître, J.-M., & Assou, S. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.04.001 · Cited by 37
Tizzano, E. F., & Zafeiriou, D. (2018) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2018.08.009 · Cited by 35
Recognition of single-stranded nucleic acids by small-molecule splicing modulators
Tang, Z., Akhter, S., Ramprasad, A., Wang, X., Reibarkh, M., Wang, J., Aryal, S., Thota, S. S., Zhao, J., Douglas, J. T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab602 · Cited by 36
“Treatment with a risdiplam analogue, SMN-C3 (10), enhanced binding between a 500-nt pre-mRNA sequence containing the GA-rich sequences and a splicing regulatory protein, far upstream element-binding protein 1 (FUBP1) (12).”
BackgroundScreening strategies for identifying RNA- and ribonucleoprotein-targeted compounds
Martin, W. J., Grandi, P., & Marcia, M. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.06.001 · Cited by 31
Metadata
- Authors
- Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., Chen, G., Zhang, N., Gabbeta, V., Vazirani, P., Bhattacharyya, A., Furia, B., Risher, N., Sheedy, J., Kong, R., Ma, J., Turpoff, A., Lee, C.-S., Zhang, X., Moon, Y.-C., Trifillis, P., Welch, E. M., Colacino, J. M., Babiak, J., Almstead, N. G., Peltz, S. W., Eng, L. A., Chen, K. S., Mull, J. L., Lynes, M. S., Rubin, L. L., Fontoura, P., Santarelli, L., Haehnke, D., McCarthy, K. D., Schmucki, R., Ebeling, M., Sivaramakrishnan, M., Ko, C.-P., Paushkin, S. V., Ratni, H., Gerlach, I., Ghosh, A., & Metzger, F.
- Affiliations
- PTC Therapeutics (United States) (US)
- University of Southern California (US)
- Spinal Muscular Atrophy Foundation (US)
- Harvard University (US)
- F. Hoffmann-La Roche AG (CH)
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.
- Corresponding author
- Peltz, Stuart W.
- Metzger, Friedrich
- ORCID
- Naryshkin, Nikolai A.
- Weetall, Marla
- Narasimhan, Jana
- Zhao, Xin
- Ling, Karen K. Y.
- Chen, Guangming
- Zhang, Nanjing
- Sheedy, Josephine
- Kong, Ronald
- Ma, Jiyuan
- Moon, Young-Choon
- Welch, Ellen M.
- Colacino, Joseph M.
- Peltz, Stuart W.
- Chen, Karen S.
- Rubin, Lee L.
- Fontoura, Paulo
- Ebeling, Martin
- Ko, Chien-Ping
- Paushkin, Sergey V.
- Ratni, Hasane
- Metzger, Friedrich
- Venue
- Science
- Published
- 2014-08-08
- Volume
- 345
- Issue
- 6197
- Pages
- 688-693
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1992985034
- Cited by
- 524
- References
- 56
- Citations by year
- 2026: 19 · 2025: 40 · 2024: 47 · 2023: 33 · 2022: 50 · 2021: 54 · 2020: 34 · 2019: 47 · 2018: 50 · 2017: 44 · 2016: 59 · 2015: 35 · 2014: 12
- FWCI
- 25.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- spinal muscular atrophy, SMN2, SMN1, alternative splicing, small molecules, SMN protein, motor function, lifespan extension, neuromuscular degeneration, compound screening
- MeSH terms
- Administration, Oral, Animals, Cells, Cultured, Coumarins, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Longevity, Muscular Atrophy, Spinal, Pyrimidinones, RNA, Messenger, Sequence Deletion, Alternative Splicing, Isocoumarins, Mice, Small Molecule Libraries, Survival of Motor Neuron 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.